MERKACIN
Back to Products100 mg\ 2ml , 500 mg\2ml
| Form | Solution for injection |
|---|---|
| Active Substance | Amikacin |
| Presentation | Vial 2 ml - No.1 |
| Treatment Category | Anti-infective agents |
About the Product
COMPOSITION
One vial contains:
Active substance: amikacin sulfate — 100 mg/2 ml or 500 mg/2 ml.
INDICATIONS FOR USE
- frequently recurrent infections of the genitourinary tract;
- intra-abdominal infections;
- septic endocarditis;
- sepsis;
- infections of the central nervous system (CNS);
- upper respiratory tract infections;
- purulent infections of the skin and soft tissues;
- biliary tract infections;
- bone and joint infections;
- wound infections and postoperative infections.
DOSAGE AND ADMINISTRATION
Adults and adolescents: 7.5 mg/kg every 12 hours for 7–10 days.
The maximum daily dose is up to 15 mg/kg, but not exceeding 1.5 g/day.
Newborn infants:
- initial dose: 10 mg/kg;
- followed by 7.5 mg/kg every 12 hours for 7–10 days.
Premature newborn infants:
- 7.5 mg/kg every 12 hours.
For:
- respiratory tract infections;
- bacteraemia;
- septicaemia;
- complicated urinary tract infections;
- intra-abdominal infections;
- febrile neutropenia:
the recommended doses are:
- adults: 15 mg/kg once daily intravenously;
- children aged over 4 weeks: 20 mg/kg.
For uncomplicated bacterial urinary tract infections:
- 250 mg every 12 hours;
- after haemodialysis, an additional dose of 3–5 mg/kg.
For patients with burns:
- 5–7.5 mg/kg every 4–6 hours due to a shorter half-life (T½ — 1–1.5 hours).
Route of administration:
- slow intravenous injection over 2 minutes;
- intravenous infusion over 30–60 minutes (in newborns — 1–2 hours).
Duration of treatment:
- intravenous administration: 3–7 days;
- intramuscular administration: 7–10 days.
DOSAGE FORM
Vial No. 1.
PHARMACOLOGICAL PROPERTIES
Pharmacodynamics and pharmacokinetics
Mercacin is a broad-spectrum antibiotic belonging to the aminoglycoside group. It has a bactericidal effect.
The drug is highly active against Gram-negative microorganisms:
- Klebsiella;
- Pseudomonas;
- Escherichia coli;
- Proteus;
- Enterobacter;
- Serratia;
- Shigella;
- Salmonella;
- Providencia;
- Mima-Herellea;
- Citrobacter freundii,
including strains resistant to kanamycin, gentamicin, and tobramycin.
It is also active against some Gram-positive microorganisms:
- Staphylococcus (including strains resistant to penicillin, methicillin, and some cephalosporins);
- some strains of Streptococcus.
Pharmacokinetic properties:
- Bioavailability — 100%.
- Maximum plasma concentration (Cmax) after doses of 0.5 g and 0.25 g is 20 and 11.3 μg/ml, respectively.
- Effective bactericidal concentration remains in the blood for 12 hours.
- Plasma protein binding — 11–20%.
- Half-life (T½) — 2.2–4 hours.
- Elimination occurs mainly through the kidneys: 98% is excreted unchanged in urine.
CONTRAINDICATIONS
·hypersensitivity to amikacin or other antibiotics of the aminoglycoside group;
·auditory nerve neuritis;
·severe renal impairment;
· pregnancy.
ADVERSE REACTIONS
The drug is generally well tolerated. In some cases, reactions associated with individual intolerance may occur.
DRUG INTERACTIONS
- Mercacin demonstrates synergistic effects when combined with:
- carbenicillin;
- benzylpenicillin;
- cephalosporins.
- In patients with severe chronic renal impairment, concomitant use with β-lactam antibiotics may reduce the effectiveness of aminoglycosides.
- The risk of nephrotoxicity may increase when used together with:
- amphotericin B;
- vancomycin;
- methoxyflurane;
- enflurane;
- NSAIDs;
- radiocontrast agents;
- cephalothin;
- cyclosporine;
- polymyxins;
- nalidixic acid.
- Enhances the neuromuscular blocking effect of curare-like drugs.
SPECIAL PRECAUTIONS
·Patients should be under strict medical supervision due to the potential ototoxicity (hearing damage) and nephrotoxicity (kidney toxicity) associated with aminoglycosides.
·Use of the drug for more than 14 days is not recommended.
· During pregnancy and breastfeeding, the drug may be used only when there are life-saving indications.